The following four adult vaccinations have been identified for reporting in your vaxPACES Clinical Performance Dashboard for the Open Bed Campaign in order to help decrease the co-infection concerns for influenza and pneumococcal disease with COVID-19. The measures calculate a rate for each vaccine and a composite rate for those populations eligible for both the influenza and pneumococcal vaccine within a provider’s population. The performance data for each measure and the composite will be refreshed quarterly and presented to each participant based on their practice.

Influenza Vaccine

Influenza: Percentage of eligible 19 years and older who received an influenza vaccine on or between [dates of the rolling 12-month measurement period. Influenza vaccination is recommended for persons 19 years and older with some exception.

• Numerator: Number eligible 19 years and older who received a vaccination for influenza virus during July 1 of the year prior to the measurement period and June 30 of the measurement period; or prior influenza virus vaccine adverse reaction at any time during or before the measurement period.

• Denominator: Number eligible 19 years and older in the data mart.

  • Denominator Exclusion: During the measurement period, patients:

    • Are in active chemotherapy, had a bone marrow transplant, have a history of immunocompromising conditions, cochlear implants, anatomic or functional asplenia, sickle cell anemia & HB-S disease or CSF leaks any time and / or are using hospice services.

Pneumococcal Vaccine - Elderly

Pneumococcal – Elderly: Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.

• Numerator: Patients 65 years of age and older who have ever received a pneumococcal vaccination.

  • Numerator notes:

    • This measure provides credit for adults 65 years of age and older who have ever* received either the PCV13 or PPSV23 vaccine (or both).

      • Data Limitations: The two vaccines should not be co-administered and intervals for administration of the two vaccines vary slightly depending on the age, risk group, and history of vaccination. The order and timing of the vaccinations depends on certain patient characteristics (detailed in the ACIP recommendations) and are not accounted for in this assessment.2

  • Numerator options:

    • Performance Met: Pneumococcal vaccine administered or previously received.

    • Performance Not Met: Pneumococcal vaccine was not administered or previously received; reason not otherwise specified.

• Denominator: Patients 65 years of age and older at the time of the encounter during the measurement period.

  • Denominator exclusion:

    • Patient received hospice services at any time during the measurement period.

* The eligible population for the numerator and denominator does not account for patients who may or may not have received a PPSV23 and / or a PCV13 pneumococcal vaccination before 65 years of age for any reason during the trailing baseline data assessment / collection period.

Pneumococcal Vaccine - Immune Compromised

Pneumococcal – Immune Compromised: Percentage of high-risk patients 19-64 of age who received both a PPSV23 and a PCV13 pneumococcal vaccination.

• Numerator: High-risk patients, 19-64 years old who have received both a PPSV23 and a PCV13 pneumococcal vaccine.

  • Numerator notes:

    • This measure provides credit for patients considered to be at high-risk due to immune compromised conditions and are 19-64 years old and have received both vaccinations.

    • The two vaccines should not be co-administered and intervals for administration of the two vaccines vary slightly depending on the age, risk group, and history of vaccination. The order and timing of the vaccinations depends on certain patient characteristics (ACIP recommendations) are not accounted for in this assessment.

  • Numerator options:

    • Performance Met: Both PCV13 and PPSV23 pneumococcal vaccines administered or previously received,

    • Performance Not Met: The PCV13 and PPSV23 pneumococcal vaccines were not administered or previously received; reason not otherwise specified.

      • Examples: PPSV23 alone, PCV13 alone and neither vaccine administered.

  Denominator: Patients 19-64 years old who meet high-risk criteria at the time of the encounter during the measurement period.

  • Denominator exclusion:

    • Patient received hospice services at any time during the measurement period.

Pneumococcal Vaccine - Co-morbid Conditions

Pneumococcal – Co-morbid Conditions: Measure Description: Percentage of at-risk patients 19-64 of age who received a PPSV23 pneumococcal vaccination.

• Numerator: At-risk patients, 19-64 years old who received a PPSV23 pneumococcal vaccination.

  • Numerator notes:

    • This measure provides credit for patients considered to be at-risk due to certain medical conditions, are 19-64 years old and have received the PPSV23 pneumococcal vaccine. 

  • Numerator options:

    • Performance Met: Patient received the PPSV23 pneumococcal vaccine at the time of the encounter or previously administered,

    • Performance Not Met: The PPSV23 pneumococcal vaccine was not administered or previously received, reason not otherwise specified.

• Denominator: Patients 19-64 years old who meet at-risk criteria at the time of the encounter during the measurement period.

  • Denominator exclusion:

    • Patient received hospice services at any time during the measurement period.